News

The iCAPS platform can isolate and present functional GPCRs in their correct confirmation to identify selective monoclonal antibody inhibitors or activators with great specificity for more effective therapeutics.

The company is dedicated to identifying, in-licensing and developing promising therapeutic candidates. The patent, when issued, will be valid until at least 2026, while additional patents claiming the

Endonovo’s "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner

Partners will benefit from real-time multi-factorial analytics to design target-indication product concepts for rare diseases based on severity, epidemiology, gene ontology, pathways, proteinopathy, standard of care, emerging innovation,

The newly-issued patents are: US 8,729,293, US 8,735,378 and US 8,735,379. The method of use claims in these patents cover multiple inflammatory disease indications, including Duchenne muscular dystrophy

This entity was created to complement our other service offerings by providing guidance and support for all phases of the product life cycle, from product concept and early

The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases. Under the terms of the agreement, X-Chem is applying

Brodalumab binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a major

The cloud-based platform will increase efficiencies of projects and trials for pharmaceutical and biotech companies worldwide. Projecis is being used by Synergy to track projects and keep client